Skip to main content

Stay informed

This section contains all current press releases on topics and news items concerning SphingoTec. Do you want to stay informed of our latest news? With interesting corporate updates and latest product news, you are always in the picture about our activities and developments. Enter your details here and receive our regular newsletter. For all requests concerning public relations please contact press@sphingotec.de

08. August 2024
SphingoTec announces the successful closing of a Series C financing round. The raised capital will allow the company to reach profitability through sustained and strategic commercialization of its products. This includes supporting market development, out-licensing activities, and close collaboration with licensees. SphingoTec aims for global expansion, including entry into the US market.
Read more
18. June 2024
SphingoTec introduced together with Boditech Med Inc. (Boditech) at the 42nd AKI & CRRT Course in Vicenza the innovative kidney function biomarker penKid developed by SphingoTec and licensed to Boditech. introduced together with Boditech Med Inc. (Boditech) at the 42nd AKI & CRRT Course in Vicenza the innovative kidney function biomarker penKid developed by SphingoTec and licensed to Boditech.
Read more
26. March 2024
SphingoTec is pleased to announce the following appointments to its management team: Deborah Bergmann as Managing Director and Chief Executive Officer (CEO), Dr. Florian Uhle as Managing Director and Chief Medical Officer (CMO) and Nicole Witzmann as Chief Financial Officer (CFO).
Read more
05. October 2023
A new, improved formula has been developed for estimating the GFR using kidney function biomarker penKid. According to the data, penKid strongly correlates with the measured GFR (mGFR), while the penKid-based formula for estimating GFR performs better than routinely used equations.
Read more
06. September 2023
A new study and real-world data on the kidney function biomarker penKid underline its potential to monitor kidney function during acute kidney injury (AKI) and RRT and to support liberation decisions from RRT.
Read more
31. August 2023
The MDA solidifies the partnership between Boditech and SphingoTec, aiming to support the successful commercialization of the assay for the biomarker penKid on the AFIAS platforms.
Read more
09. May 2023
SphingoTec has been successfully re-certified according to ISO 13485 and received its first IVDR certificate for its IVD product sphingotest® penKid®.
Read more
04. April 2023
The Acute Disease Quality Initiative (ADQI) has published a consensus statement that strongly recommends using innovative biomarkers to improve the management of sepsis-associated acute kidney injury (SA-AKI).
Read more
23. February 2023
Diagnostic company SphingoTec is pleased to announce the appointment of Dr. Florian Uhle as the company's new Medical Director. Dr. Uhle is a subject matter expert in translating innovations into routine clinical practice with a broad experience in both clinical and corporate settings.
Read more
15. December 2022
SphingoTec announces first data on the kidney function biomarker penKid as a promising tool in supporting early initiation and liberation from RRT. Although RRT remains a pivotal measure in treating AKI complications, it is also associated with significant risks and its duration should be restricted to a minimum.
Read more
15. November 2022
Boditech Med Inc. and SphingoTec GmbH have entered into a non-exclusive royalty-bearing license agreement. Under the terms of this agreement, Boditech has obtained the rights to develop and commercialize clinical tests for the kidney function biomarker penKid on its renowned AFIAS and ichroma Point of Care platforms.
Read more
26. August 2022
Four units at the University Hospital Heidelberg and Heidelberg Kidney Center implement Proenkephalin (penKid) in a pilot biomarker-based treatment approach to diagnose AKI faster and monitor it more accurately across departments.
Read more
08. August 2022
International medical experts discussed the latest developments in diagnostic and therapeutic innovations for advancing precision medicine in critically ill patients during the 4th Scientific Symposium.
Read more
01. August 2022
New findings support the clinical value of the biomarker bio-ADM for triaging sepsis patients in ED, exceeding the prognostic performance of routine biomarkers. So far, the predictive potential of the innovative biomarker has been confirmed and used primarily in ICU. A new study, recently published, confirms its applicability in ED.
Read more
30. June 2022
Jörg Menten, previously acting as Chief Commercial Officer of the company, will focus on successfully commercializing the biomarker-based diagnostics that address high unmet needs in critical care settings. Dr. Andreas Bergmann assumes the role of CSO within SphingoTec to further develop strategic innovations.
Read more
11. April 2022
The implementation of two critical care biomarkers guides the application of a potential new drug candidate for the treatment of COVID-19 patients.
Read more
24. March 2022
New evidence supporting the use of innovative biomarkers in the early identification of organ dysfunction and risk stratification of cardiac surgery patients is reported.
Read more
17. March 2022
SphingoTec and Rivaara Labs today announced that they have entered into a multi-year distribution agreement for the commercialization of SphingoTec’s point of care diagnostic solutions in the Indian subcontinent.
Read more
15. March 2022
SphingoTec announces that its kidney function biomarker penKid is reliably identifying AKI in infants, offering a solution to the shortcomings in pediatric critical care. AKI is mostly diagnosed too late for successful intervention which leads to steep mortality rates and chronic kidney disease.
Read more
29. November 2021
SphingoTec announced the appointment of Jörg Menten as its Chief Commercial Officer. In this role, Menten will develop the global commercial strategy, oversee the expansion in diagnostic markets worldwide, strengthen existing customer relations and forge new partnerships with global IVD leaders and pharmaceutical companies.
Read more
09. September 2021
SphingoTec announces a series of presentations demonstrating the utility of its innovative biomarkers in sepsis, positively impacting diagnostic and treatment decisions for critically ill patients.
Read more
31. August 2021
Uniklinik RWTH Aachen and SphingoTec GmbH announce today that novel data on the acute care biomarkers bio-ADM and penKid will be presented at the 40th ISICEM.
Read more
23. August 2021
Diagnostics company SphingoTec GmbH announces that Dr. Gerald Möller has joined the company’s advisory board as chairman of the board.
Read more
10. June 2021
Diagnostics company SphingoTec GmbH (“SphingoTec”) announces the appointment of Dr. Angelo Moesslang as new chief financial officer (CFO) and managing director.
Read more
20. May 2021
Diagnostics company SphingoTec GmbH (“SphingoTec”) announces an expansion of its go-to-market strategy to scale its sales in Germany by creating a direct sales force for its integrated diagnostic solutions.
Read more
04. May 2021
German University Hospital Uniklinik RWTH Aachen and diagnostics company SphingoTec GmbH today announced that the endothelial function biomarker bio-ADM aids in the early risk stratification and management of patients suffering from severe COVID-19, in need for escalated intensive care treatment.
Read more
23. March 2021
Diagnostics company SphingoTec GmbH (“SphingoTec”) announced today the first published data (1) on the biomarker DPP3 that can predict the evolution of organ function and survival in septic patients. Measured on top of routinely used standard parameters, such as Lactate and Procalcitonin, DPP3 is an early indicator of short-term outcomes and patient severity.
Read more
18. February 2021
Diagnostics company SphingoTec GmbH announced today that two distinct processes are involved in the development of septic shock and that SphingoTec’s biomarkers for endothelial function (vascular integrity) and cardiovascular depression allow early identification of these underlying mechanisms requiring different interventions.
Read more
16. December 2020
SphingoTec GmbH (“SphingoTec”) announced today that the Acute Disease Quality Initiative (ADQI) recommends the use of novel biomarkers for AKI, including functional biomarkers as penKid®.
Read more
10. December 2020
The Uniklinik RWTH Aachen (“Uniklinik RWTH Aachen”) has successfully translated the collaboration for research and biomarker validation with SphingoTec GmbH (“SphingoTec”) into clinical routine.
Read more
29. September 2020

BHR Pharmaceuticals Ltd (“BHR”) and SphingoTec GmbH (“SphingoTec”) today announced that they have signed a distribution agreement for the commercialization of SphingoTec’s portfolio of diagnostics solutions in acute and critical care in UK and Ireland. 

Read more
27. August 2020
Diagnostics company SphingoTec GmbH (“SphingoTec”) announced today the publication of first data, proving that its real-time kidney function biomarker penKid® is a reliable biomarker for the diagnosis of acute kidney injury (AKI) in infants.
Read more
19. August 2020

Diagnostic company SphingoTec GmbH (SphingoTec) today announced that the Company has issued a non-brokered, unsecured convertible note facility amounting to EUR 5 million that was fully subscribed by current and new investors. 

Read more
06. August 2020

Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand Von Humboldt, CFO, will be  presenting a corporate overview at the Summer Private Company Showcase, hosted by Solebury Trout on August 10, 2020.

Read more
31. July 2020

Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced that Dr Andreas Bergman, CEO, and Ferdinand von Humboldt, CFO, will be presenting a corporate overview at the Private Healthcare Company Virtual Summer Symposium, hosted by LifeSci Partners on August 4 and 5, 2020.

Read more
22. July 2020

Diagnostics company SphingoTec GmbH (“SphingoTec”) today announced the launch of its IB10 sphingotest® bio-ADM®, a CE-IVD-marked point-of-care test to quantitatively determine blood levels of Bioactive Adrenomedullin (bio-ADM®).

Read more
18. June 2020

Diagnostics company SphingoTec GmbH (“sphingotec”) announced today the results of a working group meeting of clinical experts that discussed the utility of sphingotec’s diagnostic solutions for acute and critical care in supporting the triage, diagnosis, and management of severely ill COVID-19 patients.

Read more
14. May 2020

Diagnostics company SphingoTec GmbH (“sphingotec”) and 4TEEN4 Pharmaceuticals GmbH (“4TEEN4”) announced today the publication of new data showing that high blood levels of Dipeptidyl Peptidase 3 (DPP3) are indicating upcoming multiple organ failure and mortality risk in burn patients. 

Read more
16. April 2020

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced that it has appointed Dr. Achim Plum as Managing Director and Chief Commercial Officer (CCO) of the company.

Read more
05. March 2020

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf Germany) today reported on new data on the utility of endothelial function biomarker bioactive Adrenomedullin (bio-ADM®). 

Read more
24. February 2020

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced that data from the AdrenOSS-2 study indicate a modulating role of bioactive Adrenomedullin in septic shock. 

Read more
21. February 2020

SphingoTec GmbH (“sphingotec”) today announced that novel data on its acute care biomarkers Proenkephalin (penKid®) and Dipeptidyl Peptidase 3 (DPP3) will be presented at the 25th International Conference on Advances in Critical Care Nephrology (AKI & CRRT 2020) taking place in San Diego, CA, USA, on February 24-27, 2020.

Read more
19. February 2020

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf Germany) today announced the publication of two studies demonstrating that its kidney function biomarker Proenkephalin (penKid®) is the most accurate surrogate for assessing true glomerular filtration rate (true GFR) and is reliably predictive for acute kidney injury (AKI) in patients with severe burns.

Read more
14. January 2020

Hitado GmbH (Hitado), a Sysmex point-of-care subsidiary, and SphingoTec GmbH (sphingotec) have signed an exclusive distribution agreement for the commercialisation of the Nexus IB10 diagnostic platform by Hitado in Germany. Further, Sysmex Suisse AG will commercialise the platform in Switzerland.

Read more
13. January 2020

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf near Berlin, Germany) today announced the launch of its IB10 sphingotest® penKid®, a CE-IVD-marked point-of-care test for Proenkephalin (penKid®), the biomarker that allows real-time assessment of kidney function with a simple blood test. 

Read more
09. January 2020
The German diagnostics company sphingotec GmbH (Hennigsdorf, Germany) today announced that through its network of regional and local distribution partners it will exclusively offer the Nexus Dx IB10 immunoassay platform together with a broad portfolio of commonly used tests for acute and critical care. 

Read more
23. December 2019

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf, Germany) today announced a publication in Critical Care1 with data on 2,000 ICU patients demonstrating that sphingotec‘s proprietary biomarker bio-ADM® (Bioactive Adrenomedullin) not only identifies high-risk patients for septic shock at admission but also identifies patients in the general ICU patient population who require immediate life-saving therapeutic intervention.

Read more
20. December 2019

Diagnostics company SphingoTec GmbH ("sphingotec", Hennigsdorf Germany) today reported on the publication of novel study results of its proprietary kidney function biomarker penKid® in BMC Emergency Medicine. 

Read more
16. December 2019

Diagnostics company SphingoTec GmbH (sphingotec) today announced the publication of new study results in the European Journal of Heart Failure demonstrating that its proprietary endothelial function biomarker bio-ADM® reliably diagnoses tissue congestion and residual congestion.

Read more
15. November 2019

SphingoTec GmbH (“sphingotec”) today announced that latest advancements in the development of its portfolio of novel biomarkers and diagnostic solutions will be showcased at Medica 2019 in Düsseldorf, Germany.

Read more
26. September 2019

SphingoTec GmbH (“sphingotec”) today announced that novel data on its sphingotest® penKid® assay for Proenkephalin, a unique and proprietary biomarker for real-time assessment of kidney function, will be presented at the 32nd Annual Congress of the European Society of Intensive Care Medicine (ESICM) taking place in Berlin on September 28 to October 2, 2019.

Read more
31. August 2019

Diagnostics company SphingoTec GmbH (“sphingotec”, Hennigsdorf near Berlin, Germany) today launched IB10 sphingotest® DPP3, the first CE-IVD-marked point-of-care biomarker test able to quantify DPP3 blood-plasma levels, a novel and unique biomarker predicting outcomes in patients with cardiogenic shock at admission to intensive care units (ICUs).

Read more
19. March 2019

Diagnostics company SphingoTec GmbH reports novel applications of bio-ADM® (bio-active adrenomedullin), the very first biomarker capable to diagnose the onset of septic shock, allowing physicians earliest life-saving therapeutic interventions in sepsis critical care.

Read more
14. March 2019

German diagnostics company SphingoTec GmbH (Hennigsdorf) announced that leaders in critical care nephrology have confirmed clinical utility of the company’s glomerular filtration biomarker penKid® for early diagnosis, exclusion and monitoring of acute kidney injury (AKI). 

Read more
25. January 2019

bio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency departments (EDs) of hospitals. 

Read more
08. October 2018

German diagnostics company SphingoTec GmbH has closed a €20m growth equity financing round led by international healthcare specialist investors HBM and Wellington Partners.

Read more
22. May 2018

German diagnostics company SphingoTec GmbH (Hennigsdorf) and Nexus Dx (San Diego) have combined their technology platforms to market sphingotec’s CE-marked acute biomarkers penKid® and bio-ADM® on Nexus’ market-validated POC testing immunoassay platform IB10 to substantially improve decision-making in emergency departments (EDs) and intensive care units (ICUs).

Read more
05. January 2018

Disorders caused by a leaky vasculature are more common than most people think. Despite ICU treatment, one third of the 27 million patients globally that suffer from sepsis, and up to 20% of the more than 5 million US patients with congestive heart failure die every year from their condition. 

Read more
07. December 2017

sphingotest® bio-ADM® Assay can help reduce re-admissions and death by measuring residual congestion. Ortho Clinical Diagnostics (Ortho), a global leader of in vitro diagnostics, and SphingoTec GmbH today announced a long-term, global strategic agreement regarding the endothelial function marker, biologically active Adrenomedullin (sphingotest® bio-ADM®), which measures patients’ rate of recovery from acute heart failure, providing critical information to physicians making treatment decisions. 

Read more
01. December 2017

Researchers from other institutions can request to have their studies performed using these biomarkers. SphingoTec GmbH , a biotechnology company that develops biomarkers for the detection and management of diseases, has recently signed an agreement with Mayo Clinic to collaborate on the evaluation and use of several biomarkers that may improve the diagnosis of certain disease states, including kidney disease, breast cancer, sepsis, and cardiovascular disease.

Read more
13. October 2017

scientific paper shows proenkephalin as the new biomarker for the assessment of kidney function as a more accurate marker to timely detect impaired kidney function when compared with conventional methods

Read more
14. August 2017

German diagnostic company SphingoTec GmbH (Hennigsdorf) and Chinese Company Shuwen Biotech Co. Ltd (Deqing) have signed an agreement to market Sphingotec’s biomarkers portfolio in China.

Read more
14. May 2017

German diagnostics company SphingoTec GmbH (Hennigsdorf) and bestbion dx GmbH (Cologne) have signed an agreement to market sphingotec’s innovative sepsis and congestive heart failure test (sphingotest® bio-ADM) and acute kidney function monitoring assay (sphingotest® penKid). Under the agreement, bestbion dx will market both biomarker assays, set to improve therapy monitoring and outcomes in intensive care units and emergency departments, in Germany and Austria.

Read more
05. September 2016

A study on centenarians links sphingotec’s biomarker bio-Adrenomedullin (bio-ADM) to longevity. Human longevity has been previously linked by researchers to genetic factors, calorie restriction, and certain life-style factors such as physical activity or the Mediterranean diet. Now, Italian researchers from La Sapienza University in Rome have identified an additional factor, which significantly contributes to a longer life.

Read more
12. May 2016

New research identifies blood biomarker as decisive link between fat intake and risk for cardiovascular disesases, diabetes and obesity; spingotec‘s revolutionary sphingotest®pro-NT test measures neurotensin levels to help prevent certain diseases

Read more
16. July 2015

sphingotec, LLC, predictive diagnostic tests for cancer, cardiovascular diseases and kidney function, today announced the results of a survey gauging women’s understanding of breast cancer risk factors and their perceptions of common breast cancer screening methods. 

Read more
15. July 2015

sphingotec LLC announced today that the results of two studies examining the association between proenkephalin (pro-ENK) and incident breast cancer were published online in the Journal of Clinical Oncology. The studies, which were conducted by researchers at Skåne University Hospital in Malmö, Sweden and together encompass almost 3,500 subjects, demonstrated a strong association between low plasma concentration of the opioid precursor peptide pro-ENK and increased breast cancer risk in middle-aged and post-menopausal women independent from other possible risk factors.

Read more
05. May 2015

sphingotec, LLC, a developer of predictive diagnostic tests for cancer, cardiovascular diseases and kidney function, today announced the results of a survey gauging women’s understanding of breast cancer risk factors and their perceptions of common breast cancer screening methods.

Read more
04. February 2015

Biotech company to present how biomarkers improve breast cancer risk prediction in women under hormone replacement therapy. Cambridge, Mass. – Feb. 4, 2015 – sphingotec LLC announced today that the findings from its research seeking to improve breast cancer risk stratification for guiding hormone replacement therapy has been selected for presentation at the 14th annual St. Gallen International Breast Cancer Conference in Vienna, Austria, March 18 – 21, 2015. 

Read more
14. October 2014

SphingoTec GmbH, headquartered in Hennigsdorf, Germany with U.S. operations in Cambridge, Massachusetts, today announced that it has out-licensed two of its biomarker assays—sphingotest® pro-NT and sphingotest® pro-ENK—to GeneNews Limited (TSX:GEN). The biomarker assays will aid physicians in risk assessment for breast cancer in females in the general population.

Read more